Skip to main content
Erschienen in: Journal of Assisted Reproduction and Genetics 8/2012

01.08.2012 | ASSISTED REPRODUCTION TECHNOLOGIES

Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels

Anti-Müllerian hormone in poor responders in assisted reproductive treatment

verfasst von: Handan Celik, Devran Bıldırcın, Davut Güven, Mehmet B. Cetinkaya, Tayfun Alper, A. Sertaç Batuoğlu

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the predictive value of random serum anti-Müllerian hormone (AMH) in the assessment of ovarian response in patients with diminished ovarian reserve (DOR; diagnosed after the observation of elevated baseline levels of early follicular follicle-stimulating hormone [FSH]) who were undergoing intracytoplasmic sperm injection-embryo transfer (ICSI-ET) and to compare the random serum AMH and baseline FSH levels in these patients for the prediction of poor ovarian response.

Design

Retrospective study.

Setting

University hospital.

Patients

One hundred and thirty-nine patients who were undergoing ICSI-ET cycles with early follicular FSH level >9 IU/mL.

Intervention(s)

None.

Main Outcome Measure(s)

Poor ovarian response in ICSI-ET cycles.

Results

For the identification of women at risk of cycle cancellation, an AMH cut-off level ≤1.2 ng/mL had 97.3 % sensitivity, 31.3 % specificity, 33.9 % positive predictive value, and 96.9 % negative predictive value in the women with high baseline FSH levels. An AMH cut-off level ≥1 ng/mL had a sensitivity of 58.7 % and specificity of 95.1 % for prediction of retrieval of 4 or more oocytes. By using a serum AMH cutoff level of 1.5 ng/mL, the ongoing pregnancies were predicted with 83.3 % sensitivity and 82.5 % specificity and yielded a positive predictive value of 31.2 % and a negative predictive value 98.1 %.

Conclusion

Measurement of random serum AMH level is a useful tool in the prediction of ovarian response in patients with high serum early follicular FSH levels.
Literatur
1.
Zurück zum Zitat Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril. 2005;84:555–69.PubMedCrossRef Arslan M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril. 2005;84:555–69.PubMedCrossRef
2.
Zurück zum Zitat Scott RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril. 1995;63:1–11.PubMed Scott RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril. 1995;63:1–11.PubMed
3.
Zurück zum Zitat Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD, te Velde ER. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril. 2002;77:328–36.PubMedCrossRef Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD, te Velde ER. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril. 2002;77:328–36.PubMedCrossRef
4.
Zurück zum Zitat Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685–718.PubMedCrossRef Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12:685–718.PubMedCrossRef
5.
Zurück zum Zitat Fıçıcıoğlu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimüllerian hormone as an indicator of ovarian reserve. Fertil Steril. 2006;85:592–6.PubMedCrossRef Fıçıcıoğlu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimüllerian hormone as an indicator of ovarian reserve. Fertil Steril. 2006;85:592–6.PubMedCrossRef
6.
Zurück zum Zitat Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996;81:571–76.PubMedCrossRef Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996;81:571–76.PubMedCrossRef
7.
Zurück zum Zitat Sahmay S, Cetin M, Ocal P, Kaleli S, Senol H, Birol F, Irez T. Serum anti-müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patient. Reprod Med Biol. 2011;10:9–14.CrossRef Sahmay S, Cetin M, Ocal P, Kaleli S, Senol H, Birol F, Irez T. Serum anti-müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patient. Reprod Med Biol. 2011;10:9–14.CrossRef
8.
Zurück zum Zitat Van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, Jong FH, et al. Serum antimullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71.PubMedCrossRef Van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, Jong FH, et al. Serum antimullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–71.PubMedCrossRef
9.
Zurück zum Zitat Gruijters MJ, Visser JA, Durlinger AL, Themmen AP. Antimullerian hormone and its role in ovarian function. Mol Cell Endocrinol. 2003;211:85–90.PubMedCrossRef Gruijters MJ, Visser JA, Durlinger AL, Themmen AP. Antimullerian hormone and its role in ovarian function. Mol Cell Endocrinol. 2003;211:85–90.PubMedCrossRef
10.
Zurück zum Zitat La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio CA, et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113–30.PubMedCrossRef La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio CA, et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113–30.PubMedCrossRef
11.
Zurück zum Zitat Broer SL, Mol BWJ, Hendriks D, Broekmans FJM. The role of antimullerian hormone in predicting outcome after IVF: comparison with antral follicle count. Fertil Steril. 2009;91:705–14.PubMedCrossRef Broer SL, Mol BWJ, Hendriks D, Broekmans FJM. The role of antimullerian hormone in predicting outcome after IVF: comparison with antral follicle count. Fertil Steril. 2009;91:705–14.PubMedCrossRef
12.
Zurück zum Zitat La Marca A, Volpe A. Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol. 2006;64:603–10.CrossRef La Marca A, Volpe A. Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol. 2006;64:603–10.CrossRef
13.
Zurück zum Zitat Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91:4057–63.PubMedCrossRef Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91:4057–63.PubMedCrossRef
14.
Zurück zum Zitat Garcia JE, Jones GS, Acosta AA, Wright G. HMG/hCGfollicular maturation for oocytes aspiration: phase II, 1981. Fertil Steril. 1983;39:174–9.PubMed Garcia JE, Jones GS, Acosta AA, Wright G. HMG/hCGfollicular maturation for oocytes aspiration: phase II, 1981. Fertil Steril. 1983;39:174–9.PubMed
15.
Zurück zum Zitat Raga F, Bonilla-Musoles F, Casan EM, Bonilla F. Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome. Hum Reprod. 1999;14:1431–4.PubMedCrossRef Raga F, Bonilla-Musoles F, Casan EM, Bonilla F. Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome. Hum Reprod. 1999;14:1431–4.PubMedCrossRef
16.
Zurück zum Zitat Land J, Yarmolinskaya M, Dumoulin J, Evers J. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril. 1996;65:961–5.PubMed Land J, Yarmolinskaya M, Dumoulin J, Evers J. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril. 1996;65:961–5.PubMed
17.
Zurück zum Zitat Karande V, Gleicher N. A rational approach to the management of low responders in IVF. Hum Reprod. 1999;14:1744–9.PubMedCrossRef Karande V, Gleicher N. A rational approach to the management of low responders in IVF. Hum Reprod. 1999;14:1744–9.PubMedCrossRef
18.
Zurück zum Zitat Ferraretti AP, La Marca A, Fauser BJCM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616–24.PubMedCrossRef Ferraretti AP, La Marca A, Fauser BJCM, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26:1616–24.PubMedCrossRef
19.
Zurück zum Zitat Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman HM. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertil Steril. 2011;95:2369–72.PubMedCrossRef Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman HM. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertil Steril. 2011;95:2369–72.PubMedCrossRef
21.
Zurück zum Zitat Gleicher N, Weghofer A, Barad DH. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril. 2010;94:2824–7.PubMedCrossRef Gleicher N, Weghofer A, Barad DH. Anti-Mullerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve. Fertil Steril. 2010;94:2824–7.PubMedCrossRef
22.
Zurück zum Zitat Barad DH, Weghofer A, Gleicher N. Comparing anti-Mullerian hormone (AMH) and follicle- stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril. 2009;91:1553–5.PubMedCrossRef Barad DH, Weghofer A, Gleicher N. Comparing anti-Mullerian hormone (AMH) and follicle- stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril. 2009;91:1553–5.PubMedCrossRef
Metadaten
Titel
Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels
Anti-Müllerian hormone in poor responders in assisted reproductive treatment
verfasst von
Handan Celik
Devran Bıldırcın
Davut Güven
Mehmet B. Cetinkaya
Tayfun Alper
A. Sertaç Batuoğlu
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 8/2012
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-012-9794-y

Weitere Artikel der Ausgabe 8/2012

Journal of Assisted Reproduction and Genetics 8/2012 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.